Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been given an average rating of “Hold” by the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $21.67.
A number of research analysts have commented on the company. ValuEngine cut Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.
In other news, CEO Richard A. Md Miller purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $10.79 per share, for a total transaction of $107,900.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 46.40% of the stock is owned by corporate insiders.
Corvus Pharmaceuticals (NASDAQ:CRVS) opened at $8.24 on Friday. Corvus Pharmaceuticals has a twelve month low of $8.00 and a twelve month high of $22.14. The company has a market capitalization of $195.05, a P/E ratio of -3.06 and a beta of -1.51.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. research analysts expect that Corvus Pharmaceuticals will post -2.82 EPS for the current fiscal year.
WARNING: “Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of “Hold” by Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/corvus-pharmaceuticals-inc-crvs-given-average-recommendation-of-hold-by-brokerages.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.